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INTRODUCTION
'.

The intrace_llular mechanisms underlying- steroid i
regulation of target cells are not fully understood.
However, important events in the regulation appear to be
steroid entry into cells of the specific target tissue,
interaction of the steroid with its specific cytosol
receptor, and translocation of the steroid-receptor
complex_ to the c_ell nucleus.

Presumably this leads to

initiate messenger RNA (ribonucleic acid) and protein
synthesis (Figure 1).
An important factor in establishing. the currenti
understanding of the mechanism of steroid hormone action
I

was the- synthesis of isotopica·lly labeled compounds, . they
provided the first molecular probes to discern the
sequence of events that occur following the interaction
-

'

of a steroid hormone with a target cell (Jensen and
Jacobson,1962).
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The use of tritium ( H) labeled compounds

has also become very prominent in estrogen receptor
studies involving breast cancer.
An increased incidence of new cases of breast cancer
annually in the United States and numbers of deaths due
to the disease has created a greater interest towards
studies evaluating estrogen receptors and their role in
treatment of malignant and benign tumors.
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Mechanism of action of steroid hormones.
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suggests t:hat a tissue demonstrating estrogen receptors
should be classified as an estrogen target and

'

shoul~
I

require hormone for maintenance and growth.

I

Removal1of

estrogen should result in regression or involution of the
tissue.

In contrast,· tissue lacking estrogen .receptbrs

should not be effected by removal of endogeno..is hormone.
The first evidence of a
ation of

3

relations~ip

between the associ-

H hormones with a breast tumor and the clinical

response of .the patient to ablative hor.mone therapy was·
shown by Folca and associates in 1961 (Folca, Glascock,
and Irvine, 1961).

Other

r~search

also substantiates

Witliff's proposal showing that 25.:.40% of patients with
inoperable breast cancer have neoplasms that regress,
after either the administration or pharmacological

c~n

centrations of hormones, such as androgens and estrogens,
or removal of endogenous hormones, such as by .ovarie.ctomy
or adrenalectomy (.Kennedy, 19 7 4) •

These findings suggest
!

.

that some malignant breast tumors may be hormone
dependent.
The concept underlying endocrine therapy is that
certain twnor cells have retain!=d their ability to respond
to the same hormonal stimuli as·their normal progenitor
cells (Witliff, 1977).

It is therefore suggested
.
. that

the presence of specific estrogen receptors in human.
breast carcinomas may be predictive of a patient's

4

response to endocrine therapy (Garola and McGuire, 1978,
Witliff, 1977, and McGuire, 1975).
·
·
h uman
I
Ot h er steroi·d receptors are also present
in
I
I .

.

breast cancer. cells and may provide additional information.
For example, Horwitz et .al (1975) predict that the pre~e

sence of progesterone receptors in a tissue snould
.

'

an

even more sensitive indicator of potential responsiveness
to endocrine· therapy than the estrogen receptor.

The

basi.s for .such a prediction i.s the underlying concept
that progesterone effects require estrogen priming,
thereby inducing the synthesis of the progesterone
receptor (Figure 2).

Estradiol (E )
2

mRNA

Figure· 2.

Induction of progester.one receptor by
estradiol (McGuire et al, 1978).
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Thus; the presence of progesterone receptors in, a
"

tumor would indicate that the entire sequence, involving
estrogen binding to a cytoplasmic receptor, movement! of
I

I

the receptor complex into the nucleus, and stimulation
'

of a specific end product, can be achieved in a tumor
cell.

This would rule out the existence of a defect be-

yond the binding step (McGuire et al, 19.78).

Therefore,

the presence of progesterone receptors in cancerous '
tissue will show that the tumor remains under at least
partial endocrine control and may be classified as endocrine responsive.

In support of the prediction, reiearch
i

showed 56% of tumors with estrogen receptors also had
progesterone receptors, and tumors without estrogen '
receptors also .lacked progesterone receptors (Horwit,z
et al,· 1975).

Preliminary 'data show only those breast

tumors with progesterone receptors regressed after
endocri'ne therapy.

Continua ti on of estrogen and prq-

gesterone receptor studies together with research
toward the evaluation of other steroid receptors

d~rected
pr~sent

in.human breast carcinomas, such as androgens and glucocorticoids may give hope of treatment for those patients
I

with estrogen-receptor positive but unresponsive tumors.
In research by McGuire (1977), it was shown in
randomly tested human breast tumors that 75% were
estrogen-receptor positive (ER+), with 74% of .the ER+

..
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tumors also having progesterone receptors (PgR) and
9% of the ER- tumors having PgR.

Where primary versus
I

metastatic tumors were examined, 77% of the primary

1
I

tumors were.ER+ with 77% of them containing PgR and '66%
I

of the metastatic tumors with ER+ with only 59% of them
having PgR (Figure 3).
Danazol is an isoxazole derivative of the synthetic
steroid 17 a-ethinyltestosterone (Figure 4).

It acts

through the suppression of.gonadal function .(Chamness
.

-et -al,

1980), and may .possibly be used in future treatI

ment of hormonally dependent cancers, particularly those.
of the breast and endometrium (Jenkin, 1980).

Suppqrt

for the use of danazol was strengthened by the reported
increased incidence of breast cancer in patients with a
history· of benign breast .diseases (Humphrey and Swe:z:;dlow,
·1962, Davis et al, 1964, Veronesi and Pizzocaro, 196 8, and
1

I

Dmowski and Cohen,. 1978), and the fact that danazol 'has
been shown to .cause relief of various disorders of the
breast (Greenblatt et al, 1971, Lauersen and Wilson,!
1976, Asch and Greenblatt, 1977, and Blackmore, 1977a).
The attempts to show differences between estrogen
receptors in normal human breast.tissue and fibrocystic
tissue have thus far been unsuccessful (Terenius et :al,
1974).'

· Randomly tested tlllnors

A

(74%)PgR+

PA"

A

(77%)PgR+

Figure 3.
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Swrunary of distribution of ER and PgR in human breast tumors (McGuire,
1977).
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In recent studies, danazol has been demonstrated to

,-

have four major· pharmacologic effects:

(1) direct

inhibition of gonadotropin synthesis and/or release '
(Lauersen and Wilson, 1977, Wood et al, 1975, and
Eldridge, Dmowski and Mahesh, 1974);

(2) direct inhibition

of multiple enzymes of steroidogenesis (Barbieri et al,
1977, and Barbieri, Camick and Ryan, 1977);
action with androgen, glucocorticoid and

(3) inter-

progestero~e

receptors in target tissues (Barbieri, Lee and Ryani 1979,
and Chamness, Asch and Pauerstein, 1980); and (4) alteration of endogenous steroid metabolism (Barbieri, Lee and
Ryan, 1979, and Barbieri and Ryan, 1981).

The majority

of studies exclude pinding to the estrogen· receptor as a
possible method of action (Krey, Robbins and McEwen; 1981,
Chamness, Asch and Pauerstein, 1980, Barbieri et al; 1979,
Creange, Potts and Schane, 1979, Woods et al, 1975,
- -Dmowski et al; 1971, and Potts et al, 1974).
--

In further examination of danazol's antigonadotropic
action, Chamness, Asch and Pauerstein (1980) studied its
_ability to bind and translocate androgen, estrogen and
progesterone receptors both in vivo and in vitro in· the
rat.

Their results showed danazol bound to the proges-

terone and androgen receptors, however, only the androgen
receptor was translocated to the nucleus at effective
antigonadotropic doses.

.,
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To further understand Xhe mechanism of danazol'·s.
action in its target cells, the following in vitro study
-.-

;

i

was performed to (1) determine the specificity of danazol
· d ing
·
· ·
.b in
· d ing
·
to cytoso 1 receptors b y competitive
b in

I

e~-

periments, (2) evaluate the dose response relationship of
danazol, and (3) determine the specificity for danazol to
translocate receptors into the nucleus.

In addition, 1 an·
I

in vivo experiment was conducted to study the effects of
danazol of

cytoplasmi~

steroid receptors.in uterine,mam.
marian, hypothalamic, and adrenal tissue. Although this
research is done on non-cancerous tissue, the implications
will be beneficial in future study of rat and human carcinoma.

MATERIALS AND METHODS
Animal Care
'

Nineteen Sprague-Dawley female rats ranging 200,225.
grams in weight, were obtained from Harlan Industrie's,
Indianapolis, Indiana.

Prior to being sacrificed, they
I

were maintained for two weeks in animal quarters on

--

Purina Lab Chow (Ralston-Purina Co.) and tap water .ad
libitum.
Tissue Preparation

The rats were stunned, decapitated, exsanguated and
five tiss·ues (uterus, mammary adrenals, hypothalamus and
pituitary) were removed from each.

Irrunediately upori

excision, each tissue was placed on a chilled glass
plate, trimmed of excess fat with a razor blade, weighed
and quick frozen in dry ice and acetone.

Each tissue was

wrapped .individually in foi.l, labeled and stored in ·a
freezer for future competitive binding and dose-response
.experimen.ts.
For in vitro nuclear translocation experiments,
uteri from fourteen pre-puberal ana thirteen

post-p~beral

'
Sprague-Dawley rats were excised using the same method
as
mentioned above.

After being trimmed of excess fat; the

uteri were incubated in media consisting of 1 ml mimimal

10

. ''
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'

'
essential.media with Earle's salts and L-glutamine
(Grand Island Biological Co. ) · and 1 ml of Kreb' s Rin_ger
Bicarbol).ate Glucose, pH 7.4

(Umbreit et·al, 1964).

Forty

microliters of indicated steroids in 100% ethanol were
added to give

~

final concentration of 2 x l;-s M

an~

the

uteri·were incubated for two hours at 37°c with gentle
bubbling of 95% osygen:

5% carbon dioxide in a Dubnoff

Metabolic Shaking Incubator (GCA Precision Scientific) .
Controls were incubated with 100% ethanol.

After incu-

pation,· the tissue was blotted, weighed and quick frozen
in dry ice and acetone for later assay.
Isolation of Cytosol and Nuclear Receptors
All procedures were done· on ice.and/or in a
refrigeration unit at 4°c, unless specified otherwise.
Centrifugations were carried out (depending on the procedure, sample size and rpm speci.fication) in either a
Beckman "Airfuge", International Refrigerated Centri,fuge, ·
Model B-20 (International Equipment Co.) or an Adams
Sero-fuge·.
~utomatic

'
:

Where microli ter volumes were required, ,
micro-pipets (Oxford laboratories) were used.

Isolated cytosol

~nd

nuclear receptors were prepared

by a modification of the "methods of Williams and Gorski
(1974), Chamness et al (1979), and Pavlik and Coulson
(1976) ·•

Frozen tissue was cut into small pieces and then

homogenized in phosphate buffer .[P-buffer (5mM sodiufn

,
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phosphate-, pH 7. 4, lrnM thioglycerol, 10% ·glycerol) l, in
a seven milliliter Ten Broeck pyrex glass-glass ti~sue
grinder (about 100-150 mg tissue/ml P-buffer).
.

homogenate was centrifuged (Adams Sero-fuge)

The
'

eight-~

'

minutes at 1000 .x g; the supernatant was taken. as the
cytosol, while the pellet was resuspended in P-buffer
and·recentrifuged twice, then resuspended for one hour
in buffer with 0.4 M potassium chloride to extract
receptors from the nuclei.

The pellet was then· centri-

fuged for 10 minutes at 2000 x g (International
.)

Refrigerated Centrifuge) and the supernatant was assayed
for· nuclear receptors.
Receptor Incubations
Duplicate 200 µl aliquots of cytosol or nuclear
extract were added to SO µl of radioactive ligand, ,while
another duplicate 200 µl aliquots were added to 50 µl o·f
the same ligand with an excess of non-radioactive
competitors for determination of non-specific binding.
In addition, to measure total counts, duplicate 200, µl
·aliquots of P-buffer were added to 50 µl of radioac,tive
ligand. Final concentrations of radioactive ligand.s
.
-10
'
(New England Nuclear) were 5 x 10.
M [2,4,6,7,16,,173

H(N)] estradiol (137.1 Ci/mmole), 5 x 10

-10

M [l,2•,4,5,

3
6,7,1G,l7- H(N)] dihydrotestosterone (179.0 Ci/mmo~e),
5 x. 10

-lC

3

M [1,2,6,.7- H(N)] progesterone (101.0 Ci/mmole),
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5 x 10-lO ~ [l,2,6,7- 3H(N)] corticosterone (105.0
·•.l,c.

Ci/mmole).

Non-radioactive competitors were 1. 67· x 10-?

M diethylstibesterol, 1.67 x 10-? M
'

1.67 x 10

-1.

dihydrotesto~ter~ne,

'

M progesterone, and 1.6'7 x 10

-7

M

corticosterone (all are final concentrations) .

Incu-

· bations for cytoplasmic receptors were all three hours
at

o0 c,

while those for nuclear receptors' were three

hours at 30°c (estrogen) or 18 hours at
· progestins·and corticosteroids).

o0 c

(a'ndrogens,

Cytosoi and nuclear

extract were saved (50 µl samples) for protein
determinations.
Binding Competition Experiments
I

Cytosol was prepared in P-buffer from uteri, mammary,
adrenal, hypothalamic and pituitary tissue (assayed
separately).

Duplicate aliquots of 200 µl of cytosol

were incubated with 50 µl of radioactive steroid in ,
buffer plus 50 itl of varying concentrations· of danazol.
The danazol ·(Danocrine) was a gift from Sterling-Winthrop
Research Institute.

Binding was assayed by the hydro-

xylapatite method (HAP) and non-specific binding was 1
subtracted.
Dose Response Experiments
Cytosol was prepared in P-buffer from uterine
tissue.

Triplicate aliquots of 200 µl of cytosol were

14
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-

incubated ,with 50 µl of varying concentrations of
radioactive ligand,

Competitive binding was checked'

I'

.

with 50 µl of non-radioactive ligand added to one aliquot.
I
.

'

I

In addition, triplicate aliquots of 50 µl of radioactive
ligand were incubated with varying microliter concent
trations of cytosol, with 50 µl of non-radioactive
competitor in one aliquot to check competitive binding .•
Assay for binding Was by the HAP method and non-spec~fic
binding was subtracted.
Nuclear Translocation. Experiments
Nuclear extract was prepared in P-buffer from uteri

'

of pre- and post-pµberal rats.

In experiments with the

'

pre-puberal uteri, triplicate 200 µl aliquots of the''
nuclear extract from control, danazol and dihydro-

I'
'

testosterone (DHT) incubated tissues were added to 50'
µl aliquots of radioactive DHT with a triplicate also
containing 50 µl of non-radioactive DHT.

)
I

Post-puberal uterine experiments were performed!,
I

.

.

I

using triplicate 200 µl aliquots of the nuclear extr~ct

.

.

i

from control, .danazol, DHT, progesterone, corticosterone
'
and ~stradiol incubated uteri, with a 50 µl aliquot of
'

appropriate radioactive ligand.

To check for competiti.ve

binding a. triplicate aliquot of 200 µl nuclear extract
from each incubation with 50 µl of radioactive· steroid

I

9lus 50 µl of non-radioactive competitor was performed.

I

J5

Hydroxylapatite Assay

I

One milliliter of hydroxylapatite suspension

I

.

[2.5 grams of Bio-Rad HTP, DNA grade, per 100 ml of ITP

I

buffer (50 .m.."1 Tris and 10 mM KH Po )] was added to each
2 4
tube at the end of incubation and kept su.spended by :.
occasibnal vortexing (Fisher Scientific Vortex-Genie)
for 30 minutes.

The HAP was then centrifuged 1.5 minutes

at 1000 x g, resuspended in 1.5 ml of fresh P-buffer, and
recentrifuged; this wash was completed twice more.

One

milliliter of 100% ethanol was then added to each pellet
to extract the radioactive steroid, which was then

~ounted

in 5 ml of scintil"lation fluid (19 gm PPO and 1. 9 gl\l
POPOP/3.8 L toluene).

All counts were made in a Hewlett-

Packard Tri-Carb 300 scintillation counter at Maxey Flats
Low-Level Nuclear Waste Disposal Site.
Protein Assay
Protein concentrations were determined by a

mo~if i-:,

cation of the Lowry Method (Lowry et al, 1951).

Toi'

precipitate proteins, cold 10% trichloroacetic acid1was
added to 50 µl.of cytosol or nuclear extract in a
cellulose nitrate tube (Beckman, 175 µl capacity) and
centrifuged in a Beckman Airfuge at 20 psi for 5 minutes.
I

The supernatant was aspirated with a disposable tra~sfer
pipet.

To. the prate.in precipitate, 100 µl of. 3N. so?ium

hydroxide was added, stirred with a toothpick and

I
s~t
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,j
,j'

i

aside for -10 minutes.
50 µl)

I

.]

Two concentr.ations ( 10

µ1

and'

I

of the protein mixture and of a bovine serum

albumin standard (1 gm/ml) were added to separate te:st
I

tubes and brought to o~s ml.with distilled water.

The

remaining procedures were identical with those of Lowry
et al (1951).

Measurement of protein concentr·ations

were made in a Bausch and Lomb Spectronic 70, and protein
was expressed in mg/ml.
In Yivo Experiment

.

Twenty-four female S/D rats were divided into two
groups.

The first group was given daily intramuscul'ar

(IM) inject{ons of dariazol (4 mg/kg body weight)
suspended in Planters Peanut Oil.
continued for fourteen days.

This treatment

The control group

received daily IM injections of peanut oil only for
fourteen days.

On treatment day nine, bilateral

ovariectomy was performed on eight of the twelve
I

expe~imental and control rats, leaving four intact ~n
each group.

Surgery was performed under anastbesia !
.

'

using Sodium Nembutal (Abbot Laboratories), (4 mg/100; gm
'

body weight) injected intraperitoneally · (IP) .

Sodiuni

'

Penicillin G 10 mg was inj"ected IM into each post- ·.
operative rat.

The ovariectomized group received an IM

injection of 100 micrograms of estradiol benzoate·on
treatment day twelve.
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Preparation of

Tissu~

All animals were sacrificed on treatment day
I.

fourteen.

.Tissues for assay· were immediately remove~,

tr-irnrned of excess fat, weighed to the nearest milligram;
I

'

dropped into an iced,

acetone-C0

pellet bath, blotted,

2
and kept frozen at -20°C until assays were ~erformed.

'

Preparation of Cytosol
All reagents used for preparation of cytosol are
listed in Table 1.

Cytosol fraction was prepared by' the

method derived by Heidemann and Wittliff for the
"Airfuge" (Heidemann and Wittliff, 1979).
were prepared, in the same. manner..

Bec~man

All tissues

The· frozen ·minced'

tissue was homogeriized in cold phosphate bu~fe~ (2.0 ml/
gm

All

tissue) with a Ten Broeck glass-glass homogenizer.
prepa~ations

were kept on ice

at all times.

Using
I
I

an Oxford adjustable sampler micropipetting system,
0.175 ml of cytosol was added to pre-cooled cellulose
I

nitrate tubes (Beckman Instruments, Inc.) and placed!in
i

the pre-cooled (4°C) head of a fixed-angle rotor type
.

I
I

A-100 Beckman Airfuge (Beckman Instruments, (Inc._) and
centrifuged at 110,000 x g (24 psi) for 10 minutes.
Tbe protein concentration
of the supernatant
was
.
.
confirmed later by" a modified Lowry method (Lowry,
et al. , 1951).
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T~BLE

l

REAGENTS

Danazol

Brandname Danocrine, gift of
Winthrop Research Institute:

Sterl~ng

3

i-17~-est~adiol, progesterone,
dihydrotestosterone, corticosteron~;
dissolved initially in absolute
alcohol then diluted with phosphate
buffer (pH 7.4) to appropriate
'
concentrations (New England Nuclear,
Corp.).

Hormones

Diethylstibesterol, progesterone,
dihydrotestosterone, corticosterone;
dissolved initially in absolute
alcohol then diluted to appropriate
concentrations with phosphate buffer
(pH 7.4) (Sigma Chemical, Co.).
Hydroxylapatite
Suspension

100 ml TP buffer plus 2.5 gm DNAgrade Bio Gel HTP hydroxylapatite
(Bio-Rad) , pH adjusted to 7. 2 •.

Phosphate Buffer

5 mM sodium phosphate, pH 7. 4; 1
monothioglycerol; 10% glycerol.

I
2% Na co in 0.1 N NaOH.
2 3
0.5% CaS0 ··5 H 0 in 1% Na or K tartrii.te.
4
2
25 ml reagent A plus 0.5 ml reagent B
(mixed fresh daily).
·

Reagent A
Reagent B
Reagent C

1:1, Phenol Falin Reagent: distill~d
water (mixed fresh daily).

Reagent, D
Scintiverse
T_ris Buffer
Wash Buffer

'

m¥

r™

Universal LSC Cocktail (Fisher
Scientific, Co.).
50 mM Tris, .10 mM KH Po , I! 7.2 at 4°C.
2 4
·Phosphate Buffer, pH 7.4; plus 1%;
(V/V) Tween 80.
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Hydroxylapatite Micromethod
All reagents used for the hydroxylopatite micromethod are listed in Table 1.

The Oxford adjustable,

micropipette system was used for all

micropipettin~.:'

'
"From pooled centrifuged supernatant (cytosol fraction),
0.05 ml aliquots were incubated in duplicate for four
hours at 4°C in 0.45 ml polyethylene microtubes (Bio-Rad
Laboratories) with .0.05 pmol (O.l ml of

~x

10-lO) 3 H-

labeled hormone in 0 .1 ml phosphate buff er.

A paraL).el

tube contained a 100-fold excess of competing unlabeled
hormone.

After incubation, 0.06 ml of hydroxylapatite

(HAP) suspension was added to each microtube.

After

vortex, further incubation for 30 minutes was completed
with gentle vortex every ten minutes.

The microtubes
'.

were then centrifuged for 30 seconds in a pre-cooled'

Adams-Sero Fuge centrifuge (Clay-Adams, Inc.) at 1000 x g.
The pellets were washed twice with 0.2 ml wash

buffe~,

with centrifugation and gentle aspiration after each·
wash.

After the final wa~h, centrifugation and

aspiration, the resulting pellet in the end of themicrotube was cut off and dropped into a scintillation
vial,

Scintiverse I (Fisher Scientific, Co.) or Insta

Gel (Packard) scintillation Cocktail (10 ml) was

add~d

to

each vial and all vials were counted for radioactivity in
a Packard Tri-carb liquid scintillation counter (Model
300-C).

This method is summarized in Figure 4.

,.•.'
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Sacrifice S/D Rat

...

I

+

~-

Remove tissue, weigh, freeze

+
Homogenize in P0

buffer (2 ml/gm tissue)

4

l
I

I
I!

+

•

Centrifuge 100,000 x g for 10 minutes

+
Supernatant (cytosol fraction)

+

Hydroxylapatite assay·
a.

b.

Cytosol (0.05ml)
'plus

"

Cytosol (0.05 ml)

0.10 ml H-compound
(duplicate)

plus
O.1 ml ·3 H-compound pl us
(lOOx excess) competitor

Incubate 4 hrs., 4°C

Incubate 4 hrs., 4°C

3

I

Add hydroxylapatite 0,06 ml
Incubate 30 min., 4°C
Vortex every 10 min.

+
Wash 2 x, 0.2 ml
Buff er - Tween 80

.+
Centrifuge 1000 x g, 30 sec.

+

Cut tip off with pellet

+

Count in Liquid Scintillation Counter

'. Hydroxylapatite Micromethod
Figure 4 .

RESULTS
To evaluate the validity of the HAP assay and to
determine conditions ·to be used in later experiments,
titration curves were run for both 3 u-estradiol and
cytosol.

Specific activity was measured in counts per·

minute/mg of protein.

Figure five shows a

relationship when the concentration of

3

dose~response

H-estradi~l was

reduced in the incubate, in the presence of 200 µl of ,'
cytosol.

.

.

Likewise, by the condition of increasing

amounts of cytosol, the expected dose relationship was·
seen in specific activity.

This indicates as the cytosol

.was increased, the amounts of cytosol receptors were
'increased, therefore the increase in specific binding ..
'

From these data, experimental protocol for all succeeding
experiments called for the use of 10- 9 M estradiol and
200 µl cytosol.
In the first series of experiments performed, the
competition for steroid receptors with increasing doses
of danazol were performed in various tissues.

The

r·esults of these experiments are shown in figures six~
seven, eight and table two, and.Bre expressed as a
percent of control binding.

In all experiments, danazol

exhibited a dose-response competition with steroid
receptors.

Figure six shows that in mammary tissue,

competition with the androgen receptor exceeded all
.•21

,.,
22

other steroid receptors.
~··

Binding was 58% of the control

at the physiological concentration of

10~ 9 M danazol

I

compared .to 88% of the control values of estradiol.

l

Danazol was the most efficient comoetitor
of the androgen
, •
I
'
receptor in uterine tissue, with.a value of 80% of ihe
·control ·at 10- 9 M (Figure 7).

The competition for

steroid receptors in pooled adrenal tissue is. shown in
figure eight.

This figure shows poor competition with

all steroid receptors at 10 -9 M danazol and strong
'
-5
competition at the pharmacological dose of 10
M.

1

Due to the lack of cytosol for hypothalamic tissues,
only two assays were performed.
dose of 10

-9

Using only the test

M, results show in table one that danazol
'

''

competedinost effectively with the DHT receptor (73% of
•,

control) followed by progesterone (86%), corticosterone
:
(90%) and estradiol (91%).

Table

z.

Danazol competition for steroid receptorslin
hypothalamic tissue.
I

I

Incubation conditions· Estradiol
Danazol (10- 9 M)

91*

DHT Progesterone

73

86

Corticosi::erone

90

*Mean percent of cytosol alone which was taken as 100%.
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A single test was performed with pooled pituitary
'

cytosol, showing that danazol at 10- 9 M did compete with
the DHT receptor (65% 0£ control).
A comparison of steroid binding competition by
danazol at 10- 9 M is seen in table three. This table
summerizes the data that danazol competes more favorably
with the androgen receptor in all tissues with a mean of
76% of the control followed by estradiol (91%),
progesterone (92%), and corticosterone'(951) . .
In vitro translocation experiments of steroid cytosol·
receptors were performed to better de_termine receptor
specificity and biological ·function.

The first experi-

ments were performed on 25 day old, pre-puberal uterine
tissue and the results are·shown in table four.
Compa·red to the control specific activity of 426 cpm/mg
protein, incubation with 10-

9

M DHT resulted in a 146%

increase· over the control with a mean specific activity
-6
:
of 1050 cpm/mg protein (P<.l). Danazol at 10
M translocated the androgen receptor 85% over the control.!
I

_In all.experiments in which in vitro translocation
was evaluated in adult uterine tissue, danazol did

~ot

signficantly elevate nuclear receptors in any of the
steroids tested (Table 5).

Danazol translocated the DHT

receptor most successfully with a value of 68%
over the control.

Incubation with respective

incr~ase
stero~ds

.'

'.r.a,ble 3.

Comparison of steroid binding competition by danazol at 10- 9 M.

Competing
Steroid Receptors

Uterus

Mammary

Adrenal

Hypothalamus

Mean

Estradiol

92*

87

92

91

91

DHT

80

58

9.3

73

76

Progesterone

89

95

98

86

92

Corticosterone

95

98

96

90

95

*Mean percent of control binding.

N

a:r-

·''
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Table ~·

In vitro t~anslocation of uterine androgeri
receptor in pre-puberal rats.

Treatment
N=6

Specific activity
cpm/rng protein

Control
DHT (l0- 9 M)
Danazol (lo- 6 Ml

426±146*
1050±762a
790±483

*Mean ± standard deviation
a

P<.l from controls

Percent increase
over control

146
85

'
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Table 5.

In vitrci translocation of uterine steroid
'receptors in adult rats.

Tre·atment
'N=6·

Specific activity
cpm/mg protein

Control
Estradiol

873±200*
1983±.393a

Danazol

1041±491

Control
DHT

349±316
971±354b

Danazol

585±692

Control

570:!:370

Progesterone

Perce~t incre~se

.over control:

127
19

178
68

1229±789

116

Danazol

694±528

22

Control

62±74

Corticosterone

95±47

53

Danazol

68±64

10

*

Mean ± standard deviation

a P<.001 from control
b P<.05

from control

-31
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demonstrated that the cytosol

recep~or

was translocated,

reflecting values that were significant for DHT (P<.05)
and highly significant for estradiol (P<.001).
The effect of 4 mg/kg of danazol for 14 days :can be
seen in Table 6·

Daily injections of danazol showed a

highly significani reduction of uterine weight expressed
either in absolute or relative weight terms in rats which
had intact ovaries.

Ovariectomized rats failed to·show a

further reduction in weight after danazol injectioqs.
The

red~ction

in uterine weight after ovariectomy is also

highly significant (P

< • 01).

Table 7 indicates that danazol has an effect on
reducing pooled adrenal weight in intact rats but shows
no additive reduction in adrenal weight after ovarfectomy.
Rats receiving daily injection of danazol (4 mg/kg
body weight) for nine days had mean ovarian weights of
130 ± 12 at the time of ovariectomy, compared to rats
receiving only the vehicle (154 ± 20) as indicated .in
'

Table

B.

This reduction in ovarian weigh"!; was higtlly

significant (P

< • 02).

The effects of danazol injections on steroid
receptors in the uterus ls shown in Table 9 .

Danazol

treated rats show a non-significant decrease.in all
receptors compared to intact rats with estrogen receptors
showing a 28% reduction.

'

However, significant differences

'

TABLE

6

EXPERIMENT I
EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE UTERINE WEIGHT

Treatment

Absolute Uterine Weight
(mg)

Relative Uterine Weight
(mg/100 gm body weight)

Intact Control (n = 4)

686 ± 30**

224 ± 14

Intact Danazol * (n = 4)

498 ± 50a

174 ± 16a

Ovariectomized Control (n = 8)

498 ± 85b

180 ± 28a

Ovariectomized Danazol * (n = 8)

489 ± lOOb

176.± 3la

*Danazol ~ 4 mg/kg/day for 14 days
**Mean ± Standard Deviation
a P < ,02 compared to Intact Control
· b P < •.01 compared to Intact Control

.

..

TABLE

7

·EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE POOLED ADRENAL WEIGHT

Treatment

Absolute· Adrenal Weight
(mg)
'**

Relative Adrenal Weight
(mg/100 gm body weight)

22.8

Intact Control

70.3

Intact Danazol *

64.8

23.5

Ovariectomized Control

57.3

22.6

Ovariectomized Danazol *

57 •.1

23.7

*Danazol = 4 kg/day for 14 days
**Mean adrenal weight calculated from pooled adrenals

..

TABLE 8

EFFECT OF DANAZOL ON ABSOLUTE OVARIAN WEIGHT

Treatment

Absolute Ovarian Weight
(mg)

Control (n

= 8)

154 ± 20 **

Danazol * (n

= 8)

130 ± 12a

*Danazol = 4 mg/kg/day for nine days
**Mean ± Standard Deviation
a P < • 02 Compared to ovariectomized controls

~;
TABJ_,E 9

PERCENT CHANGE IN RECEPTOR BINDING OF 3 H-STEROIDS .
AFTER DANAZOL INJECTIONS AND OVARIECTOMY

Tissue

Treatment

E2

intact

100

+danazol *
Uterus
ovarx
+"danazol
intact
Mammary

---

-

-

-

DHT
100

28 + **
42 + a
45 +
100

a

PROG

CORT

100

100

+

17 +

23 +

10 +

25 +

4+

20 +

24 +

8+

100

13

100

100

+danazol

2+

:I.l +.

5+

2+

ovarx

12 +

7+

8+

3t

. +danazol

15 +

12 +

10 +

10 +

- - - -- -*Danazol injectecl.-a'f dose- ol .4 mg/kg/day- Ior.14 days
**Arrows refer to increase t or decrease+ in specific binding compared to intact
control
a Significant from·controls at P< .05
----

-

-

- - - - ·-

-----

"'"'

'

I
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were seen for estrogen receptors when the rats were

·.{fl

I

ovariectomized ( 42% reduction) and when these castra tie·d
rats received danazol {45% reduction).

I

The ovariectomy

failed to reduce significantly the concentration of
other steroid receptors.

i

~he

Mammary tissue was not

significantly changed in its ability to bind steroid
receptors.
Binding data fcir hypothalamic tissue and

adrena~

glands were incomplete since they were analyzed· from !
pooled tissues.

However, they demonstrated the general

trend toward reduction of receptor binding.

DISCUSSION
I
I

The mechanism of action of danazol at the sub-i
cellular level is not completely understood.

'

·However,
I

according to

curren~

ideas of hormone action, danaz61

should bind to a specif.ic cytosol receptor and translocate it to the nucleus of that particular target cell,
where it would initiate protei.n synthesis . . It has been
well

substantiated that danazol binds most efficiently.

to the androgen receptor in various target tissues
(Chamness et al, 1980 and Barbieri et al, 1979).
also suggested that danazol .has a somewhat

low~i

It is·
affinity

for the progesterone (Chamness et al, 1980 and Barbieri
et al I ·1979) and glucocorticoid receptor (Barbieri et al,
1979), with little or no binding to the estrogen
receptor (Krey et al, 1981, Chamness et al, 1980, Woods
et al, .1975, Creange et al, 1979, Dmowski et al, 1971 and
'

Potts et al, 1974).

--

1'

Results of this study are concurrent

with these findings except for demonstrating a low

·,

. affinity binding of danazol to the estrogen receptor.
support of these data, Creange et al,

(1979) has shown

danazol competition with estrogen receptors of the
pituitary.
At physiological

doses~

danazol competed

simil~rly

••Ii th the· estrogen i progesterone and glucocorticoid

In·
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receptor,·showing a somewhat better competition with the

: 'Ji;"!·

androgen receptor (Table 3) .

in comparison, as

concentrations of danazol were increased, there was ·an
in.creased .competition for all receptors (Figures 6,
·7, and 8) .
'To check for receptor specificity and biological
'

function, in vitro translocation experiments were performed on pre- and post-puberal rats.

In vivo exper:i-

rnents by Chamness et al (1980) provides evidence that

--

''

the androgen receptor is the only .one effectively tr'ans·1oc.ated to the nucleus by danazol.

The findings of 'this

rese.arch, in contrast, show a non-statistical tendency
of danazol translocating the androgen receptor in
pre-puberal and adult rats (Table 4 and 5) along with a
somewhat lesser ability to translocate the estrogen,
progesterone and glucocorticoid receptor (Table 5).
It is generally agreed that danazol has weak
,

I

androgenic and no estrogenic or anti-estrogenic propetties, while its glucocorticoid and progestational
effects are still somewhat controversial (Dmowski, 1979,
Barbieri, et al, 1979, Dmowski et al, 1971 and Potts. et al,
1974).

Therefore, it must be concluded from this study

that the strong binding and translocation of the androgen
recept_or by danazol .is indicative of its androgenic
responses elicited in vivo.

1

The lower binding affinity

·,

•

for the estrogen, progesterone and glucocorticoid
···.~

receptor a'nd subsequent translocation of these receptors
I

may suggest the action of danazol on these receptor~. is
I

not sufficient to stimulate mRNA synthesis and thus1
biological activity.
Difficulty in obtaining good specific binding
counts was a drawback of this procedure,

It is sug-

gested that.higher counts may be obtained by a wash
buffer of 1% Tween 80 in phosphate buffer, which has been
shown to be more s.uccessful at diminishing the ·non- 1
specific binding (Garala and· McGuire, 1978) than
.phosphate buffer alone.
In vivo studies

o~

specific binding in intact rats

treated with danazol (4 mg/kg body weight) shows a nonsignificant reduction in all receptor binding in.uterine
cytosol (see Table g),

The estrogen binding in rats

receiving danazol shows a 28% reduction from controls .
. Progesterone was r·educed 23%,. DHT reduced ·17%, and· :
corticosterone reduced 13% after dana~ol injections.
These findings agree with similar studies done in the past
several years.

Barbieri found that danazol displaced DHT

receptors in rat prostate, displaced progesterone in an
estrogen-p.rimed rat _uterus, and that glucocorticoid
receptors were displaced by danazol in rat liver cy~osol
(Barbieri and Ryan, 1981).

In another study, Potts 'showed

that intact rats, pre-treated with danazol, showed

~ignificarit inhibition in the pituitary and hypothaiamic
uptake of

3

H-labeled estradiol.

(Potts, 1977).

Musich,

,,

•
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using a long term danazol at a high dosage, as opposed to
low dosage as used in this study, showed a decrease inrE-R
binding which may have been.due to the dose or the
duration of treatment (Musich, et al., 1981).

From a

different ,viewpoint, Jenkin reported that danazol
decreases the stimulatory effect on basal circulati~g '

1

'

levels of estrogen and progesterone to the uterus thereby
also directly effecting estrogen receptors in the tissue
(Jenkin, 1980).

Jenkin also stated that danazol competed

with the uterine cytosol receptor for the estradiol and
progesterone receptors.
The effect .of ovariectomy on receptor. binding was
only significant for estrogen receptors (see Table g).
The 42% reduction of estrogen binding in ovariectomized
1·ats was reduced to 45% in rats that received danazol
injections in addition to the ovariectomy.

This agrees

with studies by Bohnet, et al. (1981) who reported that
danazol prevented a compensatory increase in LH and FSH
after ·ovariectomy.

Potts found that ovariectomized rats

treated.with danazol significantly inhibited

pituita~y

and hypothalamic uptake and thus binding of 3 H-labele'd .
estradiol (Potts, 1977).

Th~se

findings· disagree with

findings by Wood who dimissed the local action by danazol
I.
on estrogen receptors when a 1000-fold excess of danazol
did not ~ffect the 3 H-estradiol binding to endometrial
'

•

•
•
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cytosol (Wood, 1975).

%-"

However,. Wood's study was -in vitro

and many times in vivo and in vitro studies cannot be
compared.
I

Other steroid receptor binding was not signif icaptl~ ·
reduce·d in Experiment. I.

The 25% reduction. in progesterone

binding after ovariectomy was nbt significant, a finding
that

diff~rs

from a study by Peters who reported that in

6varian hypofunction, a decrease in estrogen production
would produce less progesterone receptors and thus
reduced progesterone binding (Peters, et al., 1977).
Danazol injections failed to influence a change in
progesterone receptors after ovariectomy.
With respect to mammary tissue, these studies were
investigated with the hope that some data reflecting t:he
influence of danazol on mammary receptors would be
enlightening.

However, from the data presented in Table g,

mat:ure female rats, either intact or ovariectomized,
8howed no significant change in the ability to bind
steroid receptors;
The effect of danazol on the reduction of uteririe
and ovarian weights at low dose ( 4 mg/kg), long term
(2

4. days),
danazol
treatment is consis.tant with that
.
'
.

r 0 9orted by other investigators _(Jenkin, 1980) (Drn"w:;ki,
iB?l).

_This might be expected since

th~

reported

antigonadotropic effects o! danazo1 (Drnowski, 197t .• "i1d

•· ....

42
the direct effect of
(Barbieri

~nd

d~nazol

on inhibiting steroidogenesis

Ryan, 1981) should lead to a reduction in
I

uterine weight.

Adrenal weight reduction is also

I

consistent with Kitay's ~indings that estrogen~ have a
'

'stimulatory effect on the adrenal glands (Kitay; et ai.,
1963), and the more recent discovery that adrenals
possess an androgen receptor which when bound by
androgens, lowers adrenal weights (Rifka, 1978).

Potts

a1so reported a decrease in adrenal weights after dana.zol
treatment (Potts,

1974)~

The controversy .over danazol's steroid binding to
cytosol receptors remains but it has been seen that
danazol has an effect on multiple classes of steroid
receptors.

Although discrepancies from established data

have been noted, it should be remembered that in vivo·
receptor studies may reflect the i~direct effects of
danazo1.

Therefore it should not be surprising that

inconsistant receptor data might be seen.

Even with in

vitro studies discrepancies have been reported
et al., 1980)..

(Charnn~ss,·

Another possibility for disagreement on

receptor binding studies is

th~t

the metabolites of

danazol are hormonally active and may play a part in
receptor variability (Krey, 1981).

These metabolites

and their effect were not investigated.
Since steroid receptors are thermolabi·le, unstaple
proteins, possible variable resuits may be due to

'

'

'•
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incorrect sample storage or assay conditions such as :
·~·

keepiqg the sample cold enough to enhance binding actfvity.
Another consideration is that mariy receptor sites may! be
nuclear binding sit~s, so.that cytoplasmic sites alon~ may
not be an accurate display of the influence of danazol
and/or ovariectomy on recepto~ binding.

In any svent~

'.'

receptor studies are a molecular index of endocrine

function and dependency ·in a cell and improvements in·
.quantitation of receptor complexes continue to be vital
to hormone research and clinical therapy.
In summary, evidence presented in this research
indicates that danazol binds to and translocates estrogen,
.i

progesterone, glucocorticoid and androgen receptors in
vitro, though not significantly, while showing the
greatest success with the androgen receptor in·all
tissues.

The dose responsiveness of danazol was

. effectively demonstrate;d by its ·increased competition; at
pharmacological concentrations.

Furthermore, the

results indicated that danazol was most effective in
translocating the androgen receptor 'in mammary tissue.

The data from experiments performed in vivo after
the injections of danazol at a dose of.4 mg/kg/14 days
are summarized as follows:

. ''

..,...
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1). - A highly significant reduction of uterine
weight in ovariectomized and intact rats.
2).

A highly significant reduction in uterine
weight after ovariectomy.

3).

A reduction in pooled adrertal weight (intact
rats), with no additive weight reduction
after ovariectomy.

4).

A highly significant reduction in ovarian
weights after nine days of danazol
inject ions.

5).

A non-significant decrease in all uterine
receptors of danazol· treated rats compared·
to intact rats.

6).

A significant difference in ovariectomized
rats for estrogen receptors.

7),

Ovariectomy failed to reduce the concentration of other steroid receptors.

8).

Mammary tissue was not significantly changed
in its ability to bind steroid receptors.·
.
'

9),

A general trend toward reduction of receptor
binding in hypothalamic and adrenal glands.

In light of this research, as well as evidence
reported in the literature, the evaluation of receptor
binding .and nuclear translocation data, will hopefully
lead to a better understanding of normal steroid target
cells, cancer modified cells and drug interaction with
·each cell type.

The ·major objectives·. of this research

proposal have been met.

The exclusion· of the use of car-

cinogenic tiss·ue was necessary due to the difficulty

~f

the_ tec_hniques and the time necessary to develope these.
tecnhiques.

The technique for mammary carcinoma

was developed for later research.

'

indu~tion

•..

,.
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